Finance

Lists
OKUR:NASDAQ
Onkure Therapeutics Inc
USD 2,56
+0,79%
(+0,020) 1D
USD 2,56
0,00% (0,00)
After hours
Closed: 2 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OKUR...
Open
USD 2,57
High
USD 2,61
Low
USD 2,46
Mkt. cap
103,67 m
Avg. vol.
262,20 k
Volume
526,93 k
52-wk high
USD 5,38
52-wk low
USD 2,23
EPS
-USD 3,50
Beta
0,12
Shares outstanding
40,50 m
No. of employees
45
Open
USD 2,57
High
USD 2,61
Low
USD 2,46
Mkt. cap
103,67 m
Avg. vol.
262,20 k
Volume
526,93 k
52-wk high
USD 5,38
52-wk low
USD 2,23
EPS
-USD 3,50
Beta
0,12
Shares outstanding
40,50 m
No. of employees
45
News stories
From web sources and news partners
About Onkure Therapeutics Inc
CEO-
Employees45
Founded2011
HeadquartersBoulder, Colorado, Verenigde State van Amerika
Sector-
Websiteonkuretherapeutics.com
Analyst ratings
Based on 4 analysts giving stock ratings to OKUR in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for OKUR in the last 3 months.
Highest
Current USD 2,56
USD 21,00 (+720,31%)
Average
USD 17,00 (+564,06%)
Lowest
USD 14,00 (+446,88%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Biegler
Oppenheimer
Buy
Reiterated
USD 14,00
+446,9%
08/14/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
USD 14,00
+446,9%
08/14/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
USD 16,00
+525%
08/05/2026
Boris Peaker
JonesTrading
Hold
Maintained
-
-
08/05/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
USD 21,00
+720,3%
07/20/2026
Soumit Roy
JonesTrading
Buy
Maintained
USD 17,00
+564,1%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
11,92 m
10,72 m
11,71 m
12,61 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,59 m
3,40 m
3,91 m
4,29 m
Operating expense
15,50 m
14,12 m
15,62 m
16,90 m
Total operating expenses
15,50 m
14,12 m
15,62 m
16,90 m
Operating income
-15,50 m
-14,12 m
-15,62 m
-16,90 m
Other non operating income
-
-
-
-
EBT including unusual items
-14,70 m
-13,50 m
-15,16 m
-15,35 m
EBT excluding unusual items
-14,70 m
-13,50 m
-15,16 m
-15,35 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14,70 m
-13,50 m
-15,16 m
-15,35 m
Net profit margin
-
-
-
-
Earnings per share
-1,09
-0,99
-1,11
-0,31
Interest and investment income
804,00 k
628,00 k
458,00 k
1,55 m
Interest expense
-2,00 k
-6,00 k
-
-
Net interest expenses
802,00 k
622,00 k
458,00 k
1,55 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-15,39 m
-14,02 m
-15,51 m
-16,81 m
Gain or loss from assets sale
2,00 k
4,00 k
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme